tallózása szerző szerint "Szokol Bálint"

1-3 / 3

Development of a 3D Tissue Culture-Based High-Content Screening Platform That Uses Phenotypic Profiling to Discriminate Selective Inhibitors of Receptor Tyrosine Kinases.

Booij TH; Klop MJ; Yan K; Szantai-Kis C; Szokol Bálint; Őrfi László; Kéri György; van de Water B; Price LS (2016)

3D tissue cultures provide a more physiologically relevant context for the screening of compounds, compared with 2D cell cultures. Cells cultured in 3D hydrogels also show complex phenotypes, increasing the scope for ...
Novel compounds with potent CDK9 inhibitory activity for the treatment of myeloma

Czudor Zsófia; Mária Balogh; Péter Bánhegyi; Sándor Boros; Nóra Breza; Sipos Anna; Szokol Bálint; Őrfi László (2018)
Synthesis and characterization of amino acid substituted sunitinib analogues for the treatment of AML

Nemes Zoltán; Takácsné Novák Krisztina; Völgyi Gergely; Valko Klara; Béni Szabolcs; Horváth Zoltán; Szokol Bálint; Breza Nóra; Dobos Judit; Szántai-Kis Csaba; Illyés Eszter; Boros Sándor; Kok Robbert Jan; Őrfi László (2018)

Abstract Acute myeloid leukemia (AML) is the most common type of leukemia in adults. Sunitinib, a multikinase inhibitor, was the first Fms-like tyrosine kinase 3 (FLT3) inhibitor clinically used against AML. Off-target ...

1-3 / 3

Keresés